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Fibrinogen-c Proteolysis and Solubility Dynamics
During Apoptotic Mouse Liver Injury: Heparin
Prevents and Treats Liver Damage
Sujith V. W. Weerasinghe,1 David S. Moons,2 Peter J. Altshuler,1 Yatrik M. Shah,1,3 and M. Bishr Omary1,3
Fas ligand (FasL)-mediated hepatocyte apoptosis occurs in the context of acute liver injury
that can be accompanied by intravascular coagulation (IC). We tested the hypothesis that
analysis of selected protein fractions from livers undergoing apoptosis will shed light on
mechanisms that are involved in liver injury that might be amenable to intervention. Proteo-
mic analysis of the major insoluble liver proteins after FasL exposure for 4-5 hours identified
fibrinogen-c (FIB-c) dimers and FIB-c–containing high molecular mass complexes among
the major insoluble proteins visible via Coomassie blue staining. Presence of the FIB-
c–containing products was confirmed using FIB-c–specific antibodies. The FIB-c–containing
products partition selectively and quantitatively into the liver parenchyma after inducing ap-
optosis. Similar formation of FIB-c products occurs after acetaminophen administration.
The observed intrahepatic IC raised the possibility that heparin therapy may ameliorate
FasL-mediated liver injury. Notably, heparin administration in mice 4 hours before or up to
2 hours after FasL injection resulted in a dramatic reduction of liver injury—including liver
hemorrhage, serum alanine aminotransferase, caspase activation, and liver apoptosis—com-
pared with heparin-untreated mice. Heparin did not directly interfere with FasL-induced ap-
optosis in isolated hepatocytes, and heparin-treated mice survived the FasL-induced liver
injury longer compared with heparin-untreated animals. There was a sharp, near-simultane-
ous rise in FasL-induced intrahepatic apoptosis and coagulation, with IC remaining stable
while apoptosis continued to increase. Conclusion: Formation of FIB-c dimers and their high
molecular mass products are readily detectable within the liver during mouse apoptotic liver
injury. Heparin provides a potential therapeutic modality, because it not only prevents exten-
sive FasL-related liver injury but also limits the extent of injury if given at early stages of
injury exposure. (HEPATOLOGY 2011;53:1323-1332)
A
poptosis occurs in the context of acute and
chronic injury, which provides an important
target for intervention and amelioration of the
injury.1,2 A major mechanism that leads to hepatocyte
apoptosis is the interaction of a cell surface death re-
ceptor such as Fas with its ligand (the Fas ligand
[FasL]). Similarly, tumor necrosis factor a can interact
with its cell surface receptor to lead to apoptosis. Both
tumor necrosis factor a and FasL interactions with
their respective receptors lead to downstream activation
of caspases, which function as the executioners of cell
death. The activated caspases, in the context of patho-
logical conditions, cleave key cellular proteins, thereby
causing cells to undergo apoptosis. Numerous caspase
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substrates have been identified, including cytoplasmic
proteins such as keratins3,4 and nuclear proteins such
as lamins.5 Mice that are exposed to the functional
anti-Fas receptor antibody, Jo2, which serves as a FasL,
develop fulminant liver failure and die within hours af-
ter administration of the antibody,6,7 thereby mimick-
ing the cell death that occurs in the context of a vari-
ety of acute and chronic liver diseases.8
Acute liver injury is associated with several changes
in the hemostatic system that may lead to intrahepatic
or intravascular coagulation (IC) and changes that pro-
mote both bleeding and thrombosis.9 Fibrinogen, a
major blood protein that consists of three pairs of
polypeptide chains (fibrinogen Aa, Bb, and c), is syn-
thesized and secreted by liver parenchymal cells.10,11
Apart from its essential role in blood clotting, fibrino-
gen-c (FIB-c) contains binding sites for several pro-
teins, including clotting factors, growth factors, and
integrins.12,13 FIB-c forms dimers in response to
various cellular conditions through transamidation and
cross-linking of FIB-c chains between a lysine at posi-
tion 406 of one c-chain and a glutamine at position
398 or 399 of a second chain.14 High amounts of FIB-
c dimers have been detected in patients with tumors,
but not in control patients suffering from acute infec-
tion or inflammation. These findings suggest that the
amount of cross-linked FIB-c dimer may correlate with
tumor-associated fibrin deposition, and may be useful
as a biomarker.15,16 However, characterization of FIB-c
dimers during liver damage has not been studied.
Depending on the context, hemostatic imbalance in
acute liver failure (ALF) may contribute to cell injury or
may have a protective function.9 The therapeutic effect of
the anticoagulant antithrombin-III, a protease inhibitor of
thrombin, has been evaluated in dimethylnitrosamine-
and CCl4-induced rat liver damage.
17 Upon treatment
with antithrombin-III, dimethylnitrosamine-intoxicated
rats benefited, whereas CCl4-treated rats showed no
improvement, suggesting that IC may complicate certain
types of acute liver injury and contribute to its aggrava-
tion.17 In addition, pretreatment with heparin decreased
acetaminophen-induced liver injury in mice.18 Anticoagu-
lant treatment of human ALF was also reported in a few
patients. For example, nine patients with hemorrhagic di-
athesis due to acute hepatic necrosis were treated with
heparin, and none survived,19 whereas three patients with
ALF and one with severe relapse of viral hepatitis accom-
panied by IC were treated with heparin and fresh frozen
plasma and survived.19 Therefore, the efficacy of treat-
ment with heparin in the context of apoptotic liver injury
remains unclear, although the major concern is an
increased risk of bleeding.9
In this study, we initially sought to identify unique
proteins that are relatively insoluble and are associated
with FasL-associated liver apoptosis in mice. This led us
to identify FIB-c dimers and other FIB-related high mo-
lecular species as among the major insoluble proteins in
the liver after FasL administration. Based on this find-
ing, we hypothesized that pretreatment of mice with
heparin before FasL administration or treatment of mice
with heparin after FasL administration led to a protec-
tive effect. Our findings provide support for this hypoth-
esis and raise the possibility that targeted anticoagulation
may have a beneficial effect in some forms of ALF.
Materials and Methods
Toxin and Heparin Administration, Liver Tissue,
and Blood Analysis. FasL (Jo2 clone, BD Pharmin-
gen) was injected intraperitoneally into age/sex-
matched (10-12 weeks old/female) FVB/N mice (0.15
lg/g) to induce liver apoptosis. Heparin (AAP Phar-
maceuticals) was administered (dorsal midline, level of
scapula) through subcutaneous injection (20 U per
mouse, with mice weighing 25 g). Mice were sacri-
ficed by way of CO2 inhalation at the indicated time
points, or survival time was monitored for the lethality
experiments. Livers were isolated and divided into
pieces that were either stored in liquid nitrogen for
biochemical analysis or fixed in 10% formalin for he-
matoxylin and eosin (H&E) staining and histological
analysis. Blood samples were collected from the sacri-
ficed mice by way of intracardiac puncture and stored
(4C overnight) before analysis.
Serum alanine aminotransferase (ALT) levels were
determined using Vetscan-vs2 (ABAXIS) employing
the comprehensive diagnostic profile. Serum fibrinogen
levels were determined using a mouse fibrinogen
enzyme-linked immunosorbent assay kit (GenWay).
Sample Preparation and Biochemical
Analysis. High salt extraction (HSE) was performed as
described.20 Supernatants (Triton X-100 [TX-100] and
high salt fractions) were saved where necessary and
used after mixing with 2 sodium dodecyl sulfate
(SDS) sample buffer. Total liver lysates (TLL) were
prepared from liver tissues by way of homogenization
using 2 SDS sample buffer. Serum, plasma, and clot
fractions were also mixed (serum and plasma) or ho-
mogenized (clot) using 2 SDS sample buffer. Pro-
teins were separated by way of SDS–polyacrylamide
gel electrophoresis (SDS-PAGE), then stained with
Coomassie blue or transferred to polyvinylidene fluo-
ride membranes followed by blotting with antibodies
to FIB-c (Abcam), tubulin, and actin (Neomarkers),
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active caspases 3 or 7 (Cell Signaling), tissue factor
and plasminogen activator inhibitor-1 (R&D Systems),
and an antibody to keratin polypeptide 18 (K18) p29
apoptotic fragment.21
Determination of Percent Apoptotic Cells and
Extent of Hemorrhage. Apoptotic cells were detected
using a terminal deoxynucleotidyl transferase–mediated
deoxyuridine triphosphate nick-end labeling (TUNEL)
assay kit (Roche). The percentage of apoptotic cells in
the liver was determined by counting the total number
of nucleated cells (40,6-diamidino-2-phenylindole–
stained) and the number of apoptotic cells (TUNEL-
stained) in five random high-power fields. The extent of
hemorrhage replacing normal architecture was scored
qualitatively by a pathologist (D. S. M.) in a blinded
fashion as follows: 0, no hemorrhage; 1, 1%-10%
hemorrhage (mild); 2, 11%-20% (mild-moderate); 3,
20%-30% (moderate); 4, 30%-40% (moderate-severe);
and 5, >40% (severe). The scores were then used for
statistical analysis.
Statistical Analysis. All statistical analyses were per-
formed using a one-way analysis of variance or log-
rank (Mantel-Cox) test (for the lethality experiments)
using GraphPad Prism 5 statistical software.
Mass Spectrometry and N-terminal Sequencing. Mass
spectrometry was performed using standard protocols
by the Michigan Proteome Consortium (University of
Michigan). N-terminal sequencing was performed by
the Molecular Structure Facility (University of Califor-
nia, Davis).
Results
Comparison of the Liver Insoluble Protein Frac-
tions Before and After Fas-Mediated Apoptosis. We
used intraperitoneal injection of the FasL (Jo2), which is
known to induce significant liver injury manifested as apo-
ptosis and intrahepatic hemorrhage (Fig. 1A).6,7 We com-
pared the insoluble fractions of livers obtained from con-
trol and FasL-injected mice using HSE that removes
nonionic detergent–soluble and high salt buffer–soluble
proteins. Notably, three major proteins became clearly
prominent in the livers of the FasL-treated mice (Fig. 1B).
Proteolysis followed by mass spectrometry identified
bands 1-3 as FIB-a/c, FIB-c, and actin, respectively. For
band 2, the peptides that were predicted by mass spec-
trometry are displayed in bold lettering in Fig. 2A. N-ter-
minal sequencing of band 2 identified five amino acids
(Fig. 2A) of FIB-c, which indicates that band 2 (100-
kDa) is a cleaved dimer of FIB-c. It is already known that
FIB-c undergoes cleavage and dimerization during the
coagulation cascade.14,22
To confirm the findings predicted by mass spec-
trometry, we used immunoblotting with antibodies
specific to FIB-c and actin. Consistent with the mass
spectrometric and N-terminal sequence analysis, the
anti–FIB-c antibody recognized several protein species
[including 250 kDa and 100 kDa (Fig. 2B)] exclu-
sively in the livers of FasL-treated mice. The 250-kDa
and 100-kDa species (Fig. 2B) correspond to bands 1
and 2 in Fig. 1B, respectively. As expected, based on
the predicted identity of band 3 (Fig. 1B), the actin
blot demonstrated elevated levels of insoluble actin in
FasL-treated livers compared with untreated control
Fig. 1. Characterization of the insoluble liver proteins after FasL-
induced apoptosis. (A) FasL was administered to mice. After 4.5
hours, mice were sacrificed, followed by H&E staining. Note the dra-
matic hemorrhage (arrows) in FasL-treated (þ FasL) compared with
untreated (- FasL) mice. (B) Insoluble protein fractions of livers from
FasL-treated and untreated mice were isolated using HSE followed by
SDS–PAGE and Coomassie staining. Bands that showed increased in-
tensity after FasL treatment (bands 1, 2, and 3) were subjected to
mass spectrometric analysis which, in turn, predicted the identity of
bands 1-3 as: FIB-a/c (band 1), FIB-c (band 2), and actin (band 3).
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(Fig. 2B). Hepatocyte apoptosis after FasL administra-
tion was also confirmed biochemically via immuno-
blotting using an antibody that recognized cleaved
K18 after caspase digestion (Fig. 2B).
The shift in solubility of FIB-c upon induction of
apoptosis was also tested in individual fractions of liver
homogenates from mice with or without exposure to
FasL. Barely detectable levels of FIB-c monomer (50
kDa) are present in the livers under basal conditions
(Fig. 3). In contrast, the FIB-c blot of livers under-
going hepatocyte apoptosis showed two major bands
(100 kDa and 250 kDa) that are present only in the
total liver homogenate and are markedly enriched in
the pellet fraction but not in the soluble TX-100 or
high salt fractions (Fig. 3). Taken together, these find-
ings indicate that FIB-c dimerizes and becomes insolu-
ble upon FasL-mediated liver injury.
FIB-c Partitions from Plasma to the Liver During
FasL-Induced Liver Injury. The above findings led us
to hypothesize that FIB-c shifts its location from
plasma to the liver upon apoptotic injury. We tested
this hypothesis by comparing serum, plasma, and liver
FIB-c levels before and after exposure to FasL. The
FIB-c 100 kDa dimer was detected in FasL-treated
mouse serum but not in plasma, whereas this dimer
and other high molecular weight (HMW) products
were readily observed in the liver lysates (Fig. 4A). A
Fig. 2. FIB-c is the major insoluble liver protein after FasL-mediated
injury. (A) Fragment sequences of FIB-c obtained from N-terminal
sequencing (underlined) and mass spectrometry (bold) confirm the
identity of band #2 shown in Fig. 1B. (B) Prediction of mass spectro-
metric results was verified by immunoblotting using antibodies to FIB-c
and actin. The FIB-c antibody recognized several bands in the FasL-
treated liver (250 kDa and 100 kDa) that were not present in
untreated controls. These species correspond to bands 1 and 2 (Fig.
1B), respectively. The actin blot demonstrated elevated levels of actin
protein in FasL-treated livers compared with untreated controls. Forma-
tion of the K18 apoptotic fragment confirmed the hepatocyte FasL-
induced apoptosis.
Fig. 3. Solubility dynamics of FIB-c during FasL-induced liver injury.
Solubility dynamics of FIB-c during FasL-induced liver injury were ana-
lyzed biochemically by comparing the soluble TX-100 fraction, high
salt wash fraction (Salt), and insoluble fraction (Pellet) from FasL-
treated and untreated livers. TLL (Total) were used as controls. None
of the fractions showed detectable levels of FIB-c dimer in untreated
liver samples. However, FIB-c antibody faintly recognized the FIB-c
monomer (50 kDa) in the TLL and the soluble TX-100 fraction of
untreated liver. In contrast, FIB-c blot showed two major bands (100
kDa, 250 kDa) in FasL-treated TLL, but not in the soluble TX-100 and
wash fractions. A duplicate gel to that used for immunoblotting was
stained with Coomassie blue. Although the protein amounts in some
of the lanes (3, 4, 7, 8) were not enough to be visible with Coomas-
sie staining, they were readily detected by the FIB-c antibody (lane 8).
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separate analysis comparing the FIB-c dimer and
higher complexes in the clot from whole blood versus
intact liver (boxed panels in Fig. 4B) shows a clear and
marked shift from the clot to the liver. Therefore, the
FIB-c dimer and its HMW complexes accumulate in
the liver after FasL-mediated liver injury, which is con-
sistent with intrahepatic IC. The intrahepatic IC is
also supported by the increased levels of plasminogen
activator inhibitor-1 in plasma and liver upon FasL-
mediated liver injury, with concurrent increase in tis-
sue factor levels in plasma (Supporting Fig. 1).
Prophylactic Treatment with Heparin Reduces the
Extent of FasL-Induced Apoptotic Liver Injury. The
extensive intravascular coagulation within liver paren-
chyma after FasL-induced hepatocyte apoptosis raised
the hypothesis that anticoagulation using heparin may
provide a protective effect. For this, we first defined a
period whereby heparin is administered and maintains
its anticoagulant effect prior to injecting FasL. Using a
dose range of 10-100 U per mouse, we found that 20
U per mouse provided anticoagulation that is similar
to the higher tested doses (based on elevation of
plasma fibrinogen levels without leading to significant
hematoma formation, not shown). Based on this dos-
ing regimen, heparin was administered subcutaneously
followed 4 hours later by FasL administration. The
extent of injury in these mice was then compared with
mice given FasL alone (Fig. 5). Histological analysis of
the livers showed a dramatic decrease in the extent of
hemorrhage in mice that were given heparin (Fig. 5A,
Supporting Fig. 2). Heparin pretreatment also resulted
in a dramatic decrease in TUNEL staining (Fig. 5A).
These findings were supported by significantly reduced
serum ALT levels (4.8-fold) and lower liver apoptotic
cell number in the heparin-pretreated mice (Fig.
5B,C). In addition, biochemical analysis showed that
Fig. 4. Intrahepatic accumulation of FIB-c during FasL-induced injury. Mice were sacrificed 4.5 hours after FasL injection and blood compo-
nents (serum, plasma, clot) and livers were collected. (A) FIB-c antibody recognized the FIB-c dimer (100 kDa) in FasL-treated mouse serum but
not in FasL-untreated serum. FIB-c dimers and other HMW products (250 kDa) were readily observed in FasL-treated liver lysates. (B) FIB-c
dimers and other HMW products were clearly observed by immunoblotting in the clot fraction of untreated mice but not in the liver, whereas the
opposite occurs after FasL treatment. Coomassie staining of duplicate gels to those used for blotting are included as loading controls.
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the activation of caspases 3 and 7 and formation of
the K18 apoptotic fragment were markedly blunted in
mice that received heparin (Fig. 5D). These biochemi-
cal changes also paralleled the detection of the FIB-c
dimer (Fig. 5D). As expected, mice that received hepa-
rin showed elevated levels of serum fibrinogen (Sup-
porting Fig. 3), thereby confirming its anticoagulative
effect. Importantly, heparin-treated mice survived the
FasL-induced liver injury longer compared with hepa-
rin-untreated mice (Fig. 5E). Taken together, these
data indicate that prophylactic pretreatment with hepa-
rin reduces the extent of FasL-induced apoptotic liver
injury in FVB/N mice.
Therapeutic Benefit of Heparin in FasL-Induced
Liver Injury. Most cases of ALF occur in the context
of an unanticipated exposure to an insult.23,24 There-
fore, it is important to identify potential compounds
that can be used as a treatment, although prophylactic
drugs do have a role. Given the significant benefit
imparted by heparin when administered before the
FasL insult, we examined its effect as a therapeutic. In
a preliminary experiment, we verified the rapid onset
heparin action to be as early as 15 minutes after sub-
cutaneous injection (Supporting Fig. 4). For the treat-
ment experiment, mice were first given FasL, then hep-
arin 1, 2, 2.5, and 3 hours after FasL injection. At 4.5
hours (i.e., the same time point used for the experi-
ments in Fig. 1 and Fig. 5) after FasL injection, mice
were sacrificed to evaluate the extent of injury using
histological, serological, and biochemical means. Nota-
bly, treatment with heparin 1 hour and even 2 hours
after FasL administration significantly reduced hemor-
rhage compared with heparin-untreated mice (Fig. 6A,
Supporting Fig. 5). Serum ALT levels were markedly
lower (7.3-fold) in mice that received heparin treatment
1 hour after FasL injection, but not at subsequent
Fig. 5. Pretreatment with heparin reduces FasL-induced liver injury. (A) Heparin was administered to age/sex-matched mice followed by FasL
injection (4 hours after heparin), and the extent of liver damage was assessed. H&E sections show hemorrhage formation (top row) and TUNEL
staining shows apoptotic cells (bottom row). Three mice were used for each of the control and heparin-alone arms, and seven mice were used
for each of the FasL and FasLþheparin arms. Numbers in parentheses reflect the injury score (see Materials and Methods and Supporting Fig.
2). (B) Serum ALT, (C) % apoptotic cell count, and (D) biochemical analysis of the livers from the indicated treatments and controls are shown.
Note that all measured parameters are significantly less in mice that received heparin prior to FasL administration. In panel D, each lane repre-
sents an independent liver, and tubulin is shown as a loading control. (E) Heparin or saline were administered to mice (10-12 weeks old; n ¼
10 per group) followed by FasL injection (4 hours after heparin/saline), and survival time was recorded.
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times (Fig. 6B). Quantification of the apoptotic cells
showed a protective effect when heparin was given 1
hour or 2 hours after FasL administration (Fig. 6C),
which is paralleled by findings using TUNEL staining
(Fig. 6A). Similarly, the levels of activated caspases 3/7
and formation of the K18 apoptotic fragment were
decreased, particularly at the 1-hour time point (Fig.
6D). Therefore, early treatment with heparin signifi-
cantly reduces FasL-induced mouse liver injury.
Relationship of Apoptosis to Intravascular Coagu-
lation Within the Liver. We addressed the time
course of apoptosis progression versus IC within the
liver. Administration of FasL followed by analysis of
the livers at hourly intervals demonstrated that the
readily detectable activation of caspases and keratin
cleavage during apoptosis occur concurrently with
FIB-c dimer formation (Fig. 7). Notably, FIB-c dimer
formation shows a sharp rise, then remains relatively
constant as injury progresses, whereas caspase activa-
tion and keratin fragmentation also display a sharp rise
but continue to increase with time (compare lanes 6
and 7 with 8 and 9). An independent experiment
using analysis at 0.5-hour intervals showed similar
findings (Supporting Fig. 6).
Discussion
Our findings provide a model for FIB-c dynamics
during mouse liver injury (Fig. 8). Upon apoptotic
liver injury, plasma fibrinogen moves from plasma and
is deposited within liver parenchyma as part of an in-
trahepatic IC that is triggered by the apoptotic cell
injury. This process is accompanied by FIB-c cleavage,
dimerization, and formation of higher molecular
weight species that are detected exclusively in the liver
upon FasL-induced liver injury (Fig. 4). A similar
Fig. 6. Early treatment with heparin reduces FasL-induced liver injury. FasL was administered intraperitoneally followed by heparin injection 1,
2, 2.5, and 3 hours after FasL injection (n ¼ 5-7 mice per time point). After 4.5 hours of FasL injection, mice were sacrificed and liver damage
was assessed. (A) H&E staining (top row) and TUNEL staining (bottom row) showed that treatment with heparin at 1 hour and 2 hours after
FasL injection significantly reduced hemorrhage formation and apoptosis, indicative of only mild to moderate injury, compared with heparin-
untreated mice. Numbers in parentheses reflect the injury score (see Materials and Methods and Supporting Fig. 5). (B,C) Serum ALT levels and
percentage of apoptotic cells, respectively. (D) Activation of caspase 3 and 7 was markedly reduced in mice that received heparin 1 hour follow-
ing FasL injection. Consistent with the decreased caspase activation, lower levels of the K18 apoptotic fragment were detected in livers of mice
that received heparin treatment 1 hour following FasL injection compared with mice that received FasL alone. Serum ALT levels for each of the
biochemically analyzed livers of each animal are shown. Tubulin blot is included as a loading control.
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behavior of FIB-c proteolysis and solubility dynamics
also occurs in acetaminophen-mediated acute liver
injury (Supporting Fig. 7). In contrast, under basal
conditions only small amounts of fibrinogen are pres-
ent in the liver, where it is synthesized in both rodents
and humans, then secreted into the circulation.25 The
significance of the FIB-c dimer as a potential bio-
marker has been reported in cancer patients.15,16 How-
ever, to our knowledge, biochemical FIB-c changes in
the context of ALF have not been reported, although
fibrin deposition in mouse liver has been observed af-
ter acetaminophen-mediated acute injury.18 Notably,
blood clots from mice undergoing apoptosis manifest a
dramatic decrease in their 100-kDa FIB-c levels (Fig.
4B; compare lanes 2 and 5). Further studies will be
needed to determine whether loss of FIB-c dimers (or
other fibrinogen isoforms) in the clot of patients with
ALF will serve as a potential useful marker of intrahe-
patic IC and disease severity.
The approach that we used to arrive at the impor-
tance of the hemostasis pathway during ALF involved
a limited proteomic analysis aimed at the characteriza-
tion of insoluble proteins that accumulate as a conse-
quence of FasL-induced liver injury. Given the relative
short time from exposure to FasL to havesting of the
livers (4-5 hours), we predicted that any new protein
species that either appear or disappear after FasL expo-
sure are likely related to posttranslational modification
of resident proteins or to proteins derived from infil-
trating cells. The observed increase in actin (Fig. 1) is
likely due to actin that is derived from infiltrating
erythrocytes that accompany the observed hemorrhage,
although we cannot exclude the possibility of a post-
translational modification of actin that renders it
insoluble.
As a result of IC, fibrin thrombi including the FIB-
c dimer and its cleaved higher mass complexes accu-
mulate in the liver, thereby altering normal blood flow.
The consequent decreased blood flow to hepatocytes
likely results in accumulation of reactive oxygen species
and nitrogenous waste products in the liver, thereby
perpetuating the extent of liver injury. Therefore, hep-
arin is predicted to act by disrupting the injury cycle
as injury moves from an early to an intermediate stage
(Fig. 8) and preventing the deposition of fibrin
thrombi, including the FIB-c dimer and its complexes,
and facilitating adequate blood supply to liver paren-
chymal cells. Heparin does not appear to directly
Fig. 7. Time course of caspase acti-
vation, K18 caspase-mediated diges-
tion, and FIB-c dimer formation after
FasL-induced injury. Liver apoptosis
was induced by FasL injection. Mice
were sacrificed 1, 2, 3, and 4 hours
after FasL injection (n ¼ 2 mice per
time point), followed by preparation of
the total liver lysates or HSE, then im-
munoblotting using antibodies to the
indicated antigens. A tubulin blot is
included as a loading control, and a
Coomassie stain of a duplicate gel of
the HSE samples that were analyzed
by blotting is also included.
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inhibit FasL-mediated apoptosis, because heparin pre-
treatment of isolated mouse hepatocytes ex vivo did
not alter the extent of FasL-induced caspase activation
and K18 degradation (Supporting Fig. 8). We are not
able to completely separate whether Fas and intrahe-
patic coagulation act simultaneously or sequentially;
however, it appears that once significant coagulation
occurs, it does not continue to increase, whereas cas-
pase activation and apoptosis do continue to increase
(Fig. 7, Supporting Fig. 6). This finding suggests that
there may be a second wave of apoptosis/necrosis that
is inhibited by heparin. In support of this notion,
assessment of early time points after heparin pretreat-
ment followed by FasL injection showed that heparin
decreases caspase 3 activation, K18 caspase-mediated
digestion, and formation of FIB-c dimers (Supporting
Fig. 9). One important caveat is that heparin pretreat-
ment delays but does not prevent animal mortality
(Fig. 5E). This finding indicates that Fas–FasL interac-
tion continues to occur despite the presence of
heparin.
Another important finding herein is the beneficial
effect of heparin, not only to provide prophylaxis to-
ward apoptosis-associated liver injury but also to treat
the injury, which is an important distinction in terms
of potential therapeutic use. Heparin use was described
to be effective in providing protection when given
before administering acetaminophen, but was not
tested for its effect after induction of liver injury.18 In
humans, therapy for ALF is primarily supportive
unless liver transplantation is available or deemed
required,24,26 though interventions such as the admin-
istration of N-acetylcysteine in non–acetaminophen-
related ALF may be beneficial.27 Currently anticoagu-
lation is not used in human ALF because of the risk
of increased bleeding, especially in the context of inva-
sive procedures.28,29 However, it appears that patients
with ALF have complex hyper- and hypocoagulable
states,9,30 and patients undergoing liver transplantation
with international normalized ratio values of >1.5 did
well without plasma or red blood cell transfusions.31
The complex antifibrinolytic and profibrinolytic milieu
in patients with ALF suggests that a targeted anticoa-
gulation approach that is patient- and disease-specific
may be beneficial.
The dose of heparin used in our mice is predicted
to be lower than what is currently used in patients
who undergo treatment for deep venous thrombosis or
other complications related to a hypercoagulable state.
For example, the 20 U per 25 g mouse weight can be
converted to a predicted human dose of 5,000 U,
based on the recommended body surface area conver-
sion,32 which is lower than the typical 10,000 or more
USP bolus dosing that is used in adult humans before
initiating continuous infusion.33 Our study provides a
proof-of-principle approach that anticoagulation is
effective in ameliorating FasL-induced liver injury. The
use of the minimum effective dosing is of obvious
Fig. 8. Model of intrahepatic vascular coagulation and epithelial cell apoptosis dynamics in response to FasL. The early stages of FasL-
induced liver injury are manifested by limited hepatocyte apoptosis and intrahepatic vascular coagulation. This is followed at the intermediate
stages by a near-concurrent marked increase in liver caspase activation, epithelial apoptosis, and intravascular coagulation. The IC is manifested
by the formation of FIB-c dimers and HMW products within the liver, in association with a dramatic shift of FIB-c from plasma to liver. During
the late stages that follow FasL exposure, IC remains relatively unchanged, whereas hepatocyte apoptosis continues. Heparin provides a thera-
peutic modality that not only limits the extent of FasL-related liver injury when given as prophylactic but also limits the extent of injury if given at
the early stages of injury exposure.
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importance in order to minimize bleeding complica-
tions. For example, when we used doses of 50-100 U
per mouse, hematomas of variable sizes were frequently
noted proximal to the site of injection (data not
shown). The use of other fibrinolytic approaches (e.g.,
low molecular weight heparin33) may also prove
beneficial.
Acknowledgment: We thank Dr. Pavel Strnad for
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